NCT01499511|CompletedResults
Anglo-Scandinavian Cardiac Outcomes Trial: Post Trial Follow-Up Study
ASCOT-10
Loading search results
ASCOT-10
Sponsor study identifier
Secondary identifiers
EUDRACT_NUMBER
observational
1,718
1 country
1
Study Start
January 2012
Actual (reported)Primary Completion
May 30, 2015
Actual (reported)Study Completion
January 31, 2016
Actual (reported)ASCOT-10 is a follow-up study of surviving participants in the United Kingdom (UK)arm of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) which was conducted between 2000 and 2005.ASCOT's results showed substantial cardiovascular benefit from: 1) the use of a cholesterol lowering drug (atorvastatin) compared to placebo, and 2) the use of a blood-pressure lowering strategy based on amlodipine when compared to a strategy based on atenolol. ASCOT-10 will test the hypothesis that the ASCOT subjects who originally received Atorvastatin and those who received amlodipine based treatment will continue to show a cardiovascular benefit relative to those who did not, even though all the subjects have had access to optimal treatment in the interim.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 31, 2016
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 7, 2011
Actual (reported)December 26, 2011
Actual (reported)January 2012
Actual (reported)May 30, 2015
Actual (reported)January 31, 2016
Actual (reported)December 3, 2019
Actual (reported)Number of Participants Who Have Died From Cardiovascular Disease Since the End of the ASCOT Study
Number of participants who have died from cardiovascular disease since the end of the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Armstudy
16 years
Number of Participants With Non Fatal Myocardial Infarction
Morbidity of non fatal myocardial infarction after 16 years in patients recruited into the Anglo-Scandinavian Outcomes trial with two groups
16 years
Number of Participants With Non Fatal Stroke/TIA (Transient Ischaemic Attack)
Non fatal stroke and TIA (Transient Ischaemic Attack) morbidity after 16 years in patients recruited into the Anglo-Scandinavian Outcomes trial
It is follow up group from the ASCOT study, after treatment with amlodipine for 5.5 years. No treatment only follow up.
It is follow up group from the ASCOT study, after treatment with atenolol for 5.5 years. No treatment only follow up.
Subjects who participated in the Anglo-Scandinavian Cardiac Outcomes Trial in the UK
International Centre for Circulatory Health
London, W2 1LA, United Kingdom
Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005 Sep 10-16;366(9489):895-906. doi: 10.1016/S0140-6736(05)67185-1.
Plasma to be stored for future measurement of biochemical markers of cardiovascular disease
Judith A Mackay, MBBS PhD MRCP
Imperial College Healthcare NHS Trust
Peter S Sever, MBChB FRCP PhD
Imperial College London
Simon M Thom, MBBS MD FRCP
Imperial College London
1,718 participants (actual enrollment reported by the registry).
First Submitted
February 7, 2011
First Posted
December 26, 2011
Study Start
January 2012
Actual (reported)The Use of a Community-based Organization to Change Lifestyle Characteristics Related to Non Communicable Diseases
16 years
Number of Participants Who Have Developed Diabetes Since the End of the ASCOT Trial
16 years
Number of Participants Who Have Undergone Coronary/Peripheral Re-vascularisation Procedures Since the End of the ASCOT Trial
16 years
Number of Participants Who Have Required Renal Replacement Therapy (Dialysis or Kidney Transplant) Since the End of the ASCOT Trial
16 years
Number of Participants Who Have Experienced a Transient Ischaemic Attack (TIA) Since the End of the ASCOT Trial
16 years
Contact the study team to confirm eligibility.
Primary Completion
May 30, 2015
Actual (reported)Study Completion
January 31, 2016
Actual (reported)Last Updated
December 3, 2019
Results First Posted
December 3, 2019
Record last verified: 2019-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: